The A20 protein interacts with the Epstein-Barr virus latent membrane protein 1 (LMP1) and alters the LMP1/TRAF1/TRADD complex

被引:38
作者
Fries, KL
Miller, WE
Raab-Traub, N [1 ]
机构
[1] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
关键词
D O I
10.1006/viro.1999.9980
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) interacts with the tumor necrosis factor receptor (TNFR)-associated factor (TRAF) molecules, which are important for LMP1-mediated signaling. Two domains of LMP1 can independently activate NF-kB, carboxyl-terminal activating region 1 (CTAR1) and CTAR2. The activation of NF-kB by CTAR1 occurs through direct interaction of LMP1 with the TRAF molecules, whereas CTAR2 interacts with the TNFR-associated death domain protein (TRADD) to activate NF-kB and the c-Jun N-terminal kinase (JNK). A20, which is induced by LMP1 through NF-kB, can block NF-kB activation from both domains of LMP1 and inhibit JNK activation from CTAR2. A20 also has been shown to associate with TRAF1 and TRAF2. In this study, an interaction between LMP1 and A20 was detected that was increased by TRAF2 overexpression. A20 did not affect the association of TRAF1 with TRAF2 but did displace TRAF1 from the LMP1 complex. The interaction of LMP1 and TRADD was decreased in the presence of A20, and the LMP1-A20 association was decreased by TRADD, suggesting that A20 and TRADD both interact with LMP1 and may compete for binding. These data indicate that A20 alters the interactions between LMP1 and the TRAF molecules and TRADD, affecting the activation of NF-kB, JNK, and perhaps other TRAF-mediated signaling events. (C) 1999 Academic Press.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 39 条
[11]  
Geser A., 1983, EUR J CANCER CLIN ON, V19, P1394
[12]   EPSTEIN-BARR VIRUS-INDUCED B-CELL LYMPHOMA AFTER RENAL-TRANSPLANTATION - ACYCLOVIR THERAPY AND TRANSITION FROM POLYCLONAL TO MONOCLONAL B-CELL PROLIFERATION [J].
HANTO, DW ;
FRIZZERA, G ;
GAJLPECZALSKA, KJ ;
SAKAMOTO, K ;
PURTILO, DT ;
BALFOUR, HH ;
SIMMONS, RL ;
NAJARIAN, JS .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (15) :913-918
[13]   INDUCTION OF BCL-2 EXPRESSION BY EPSTEIN-BARR-VIRUS LATENT MEMBRANE PROTEIN-1 PROTECTS INFECTED B-CELLS FROM PROGRAMMED CELL-DEATH [J].
HENDERSON, S ;
ROWE, M ;
GREGORY, C ;
CROOMCARTER, D ;
WANG, F ;
LONGNECKER, R ;
KIEFF, E ;
RICKINSON, A .
CELL, 1991, 65 (07) :1107-1115
[14]   TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways [J].
Hsu, HL ;
Shu, HB ;
Pan, MG ;
Goeddel, DV .
CELL, 1996, 84 (02) :299-308
[15]  
HU HM, 1994, J BIOL CHEM, V269, P30069
[16]  
HUEN DS, 1995, ONCOGENE, V10, P549
[17]   The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation [J].
Izumi, KM ;
Kaye, KM ;
Kieff, ED .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (04) :1447-1452
[18]   The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappa B [J].
Izumi, KM ;
Kieff, ED .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (23) :12592-12597
[19]  
Jaattela M, 1996, J IMMUNOL, V156, P1166
[20]   LATENT AND REPLICATING FORMS OF EPSTEIN-BARR VIRUS-DNA IN LYMPHOMAS AND LYMPHOPROLIFERATIVE DISEASES [J].
KATZ, BZ ;
RAABTRAUB, N ;
MILLER, G .
JOURNAL OF INFECTIOUS DISEASES, 1989, 160 (04) :589-598